Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex Extends Time Dependent Inhibition Service to Include the Cytochrome P450 Isoform, CYP2B6

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that it has extended its time-dependent inhibition service to include the cytochrome P450 (CYP450) isoform, CYP2B6.

Inhibition of the various CYP450 isoforms, including CYP2B6, is one of the main causes of drug-drug interactions. Drug-drug interactions can cause otherwise safe medicines to accumulate in the body resulting in toxicity.

A US FDA update paper by Huang et al., 2008 (J Clin Pharmacol 48; 662-670) has highlighted the importance of CYP2B6 in clinical interactions and recommends that CYP2B6 should be investigated in vitro when assessing whether enzyme inhibition or induction has the potential to produce a drug interaction.

CYP450 inhibition can produce either reversible or irreversible drug-drug interactions. Time-dependent inhibition assays identify compounds which have the potential to form an irreversible drug-drug interaction. These types of drug-drug interactions, although less common, are more serious because the inhibited enzyme must be re-synthesised by the liver before metabolism is restored.

The range of validated CYP450 isoforms in Cyprotex’s time-dependent inhibition service now include CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. These isoforms are also available in Cyprotex’s CYP450 reversible inhibition service. Used in combination, these assays act as valuable tools in identifying potential drug-drug interactions, and distinguishing between reversible and irreversible inhibition.

Dr. Katya Tsaioun, Cyprotex’s Chief Scientific Officer, comments on the launch of this new service: “Time-dependent CYP inhibition is a growing concern to the pharmaceutical industry because of the increasing proportion of patients on multiple medications. Due to the serious toxicity implications of irreversible CYP interactions, understanding potential drug-drug interaction liabilities at an early stage in drug discovery is critical. Cyprotex is pleased to provide drug-discovery companies with the most advanced assays for identifying potentials for drug-drug interactions early in the process.”
 

Enquiries:

Cyprotex PLC
Dr Katya Tsaioun, Chief Scientific Officer
Dr Anthony Baxter, Chief Executive Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com
www.singercm.com

Financial Dynamics
Ben Brewerton
Ben Atwell
Mo Noonan
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com


 

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close